New mechanism of heart protection by angiotensin receptor blockers

Area of Science:

• Cardiology
• Pharmacology
• Molecular Biology

Background:

• Cardiac hypertrophy, common in hypertension, increases risks of arrhythmia, stroke, sudden death, and heart failure.
• Mechanical stretching is a known trigger for cardiac hypertrophy.
• Angiotensin receptor blockers (ARBs) are investigated for their role in mitigating stretch-induced hypertrophic responses.

Purpose of the Study:

• To investigate the role of AT(1) receptors in mechanical stretch-induced cardiac hypertrophy.
• To differentiate between competitive antagonism and inverse agonism of ARBs on AT(1) receptors.
• To explore the clinical significance of ARB inverse agonism, independent of angiotensin II.

Main Methods:

• Utilizing models of mechanical stretching to induce cardiac hypertrophy.
• Examining the effects of various ARBs, including candesartan, on AT(1) receptor activity.
• Assessing receptor activity in the presence and absence of angiotensin II.

Main Results:

• AT(1) receptors are implicated in the hypertrophic response to mechanical stretching.
• The effects of mechanical stretching on cardiac hypertrophy can be independent of angiotensin II.
• Two distinct mechanisms of ARBs were identified: competitive antagonism and inverse agonism.
• Candesartan demonstrated inverse agonism on AT(1) receptors, inhibiting receptor activity without ligands.

Conclusions:

• Inverse agonism by ARBs like candesartan offers a potential therapeutic strategy for cardiac hypertrophy.
• The clinical efficacy of candesartan may depend on angiotensin II levels and AT(1) receptor expression.
• Understanding ARB mechanisms, particularly inverse agonism, is crucial for managing hypertensive cardiac hypertrophy.